Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_4
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (66.7%)
Phase 41 (33.3%)

Trials by Status

not_yet_recruiting133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

NCT06937385
completedphase_4

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

NCT03913091
completedphase_3

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03682302

Clinical Trials (3)

Showing 3 of 3 trials
NCT06937385Phase 3

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

Not Yet Recruiting
NCT03913091Phase 4

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

Completed
NCT03682302Phase 3

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3